Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,881 25 apr 2024 17:35
  • -0,024 (-2,60%) Dagrange 0,875 - 0,910
  • 4.203.859 Gem. (3M) 6,9M

Sectornieuws - biotech

6.429 Posts
Pagina: «« 1 ... 135 136 137 138 139 ... 322 »» | Laatste | Omlaag ↓
  1. machmit 26 november 2015 21:16
    Vandaag in NRC: Big Pharma ( de grote farmaceuten) zoeken klapper bij de kleintjes. "Een geneesmiddel op de markt brengen kost voor grote farmaceuten 2 miljard dollar, omdat ze alle mislukkingen ook moeten meerekenen. Als ze een bedrijf overnemen, stappen ze veel later in en hoeven ze maar een paar jaar ontwikkeling te financieren. Van de medicijnen die nu op de markt komen, komt 60 tot 70 procent tegenwoordig van kleinere biotechbedrijven".
    Ik wijs nog maar eens op de innige samenwerking van Pharming met Valeant.
    "The acquisition of our US partner Salix by Valeant Pharmaceuticals International in the first half of 2015 has led to a revision in the way Ruconest® is being marketed in the US. Valeant is concentrating sales effort on larger HAE clinics, which deal with significant numbers of patients with acute HAE attacks, the indication for which Ruconest® is approved.In July, we went live with the “HAEi GAP” (the Hereditary Angioedema International Patient Organization’s Global Access Program) in collaboration with Clinigen Group PLC, to provide patients with access to Ruconest® in countries where the drug is not yet commercial available. On behalf of their patients, physicians may request Ruconest® through an ethically and regulation-compliant ”Named Patient Program” mechanism. The first requests under this program have already been received by Clinigen.
    We have stepped up our research and development activities. We have two ongoing studies: A randomised, double-blind placebo controlled Phase II study for
    Ruconest® in prophylaxis of HAE, and a Phase II pediatric study for treatment of HAE in young children (2-13 years of age), progressing during the quarter. These studies are expected to finish during the first half of 2016.After the quarter end, we received notification from the U.S. Food and Drug Administration (FDA) that they have granted Ruconest® extended data exclusivity (from 7 years to 12years), which means that no bio-similar version of Ruconest® can be approved in the US before July 2026. This should enable us to develop our current pipeline of products to full commercialisation before revenues from Ruconest® come under generic competition". (http://haei.org/wp-content/uploads/2015/11/HAEi_Newsletter_November2015_MV.pdf)
  2. forum rang 10 voda 26 november 2015 22:31
    'Merck zet allergiedivisie in etalage'

    Gepubliceerd op 26 nov 2015 om 22:01 | Views: 182

    DARMSTADT (AFN/BLOOMBERG) - Het Duitse chemie- en farmacieconcern Merck overweegt een verkoop van zijn allergiedivisie. Het bedrijf is er volgens ingewijden alles aan gelegen om de schuld terug te brengen na de miljardenovername van Sigma-Aldrich, zo werd donderdag bekend.

    Allergopharma, het onderdeel dat volgens de bronnen in de etalage wordt gezet, zou Merck circa 600 miljoen euro moeten opleveren. Meerdere partijen waaronder concurrerende farmaceuten alsook private investeerders zouden wel oren hebben naar het onderdeel.

    Merck kocht Sigma-Aldich vorig jaar voor omgerekend 13,1 miljard euro. Het betekende de grootste overname ooit voor Merck.
  3. forum rang 10 voda 27 november 2015 14:25
    Kiadis Pharma maakt goede voortgang met medicijn tegen bloedkanker

    AMSTERDAM (Dow Jones)--Kiadis Pharma nv (KDS.AE) maakte goede voortgang met de ontwikkeling van zijn belangrijkste potentiele medicijn in de behandeling tegen leukemie en andere bloedaandoeningen, ATIR101T, zo meldt het bedrijf vrijdag voorbeurs tijdens de publicatie van een interim management statement.

    Het concern meldt dat de volledige inschrijving voor de Fase 2 studie voor het middel is afgerond. Eind eerste kwartaal 2016 wordt het eindpunt bereikt in de studie voor de laatste patienten, waarna begin tweede kwartaal 2016 de resultaten van de studie zullen volgens.

    Een tweede studie, die parallel loopt aan de lopende Fase 2-studie en zich focust op het testen van een herhaling van de toediening van het middel, is inmiddels geinitieerd, middels de inschrijving van een eerste patient.

    Tot slot meldt het concern dat de opzet en ontwikkeling van een gesloten productieproces - om dit proces vervolgens te kunnen automatiseren - volgens plan verloopt.

    In de eerste negen maanden van 2015 genereerde het concern geen inkomsten. Kiadis boekte in de eerste negen maanden van 2015 een nettoverlies van EUR13,1 miljoen.

    De kaspositie noteerde eind september 2015 op EUR31,3 miljoen. Het eigen vermogen bedroeg eind 2015 EUR29,1 miljoen.

    Sinds begin juli 2015 staat het concern genoteerd aan Euronext Brussel en Amsterdam. De bruto-opbrengst van de beursgang bedroeg EUR34,7 miljoen en de netto-opbrengst kwam uit op EUR31,2 miljoen.

    Het aandeel sloot donderdag op EUR11,74.

    - Door Patrick Buis; Dow Jones Nieuwsdienst; +31 20 571 52 00; patrick.buis@wsj.com
  4. forum rang 10 voda 27 november 2015 14:27
    Kiadis resultaten 1ste 9 mnd conform verwachting - Market Talk


    AMSTERDAM (Dow Jones)--Kiadis (KDS.AE) rapporteerde voorbeurs over de eerste negen maanden van 2015 conform de verwachting een nettoverlies van EUR13 miljoen en een kaspositie van EUR31 miljoen, meldt KBC, eraan toevoegend te verwachten dat het concern op de korte termijn meer details zal publiceren over de ATIR Fase 2 studie. KBC-analist Jan de Kerpel hanteert een buy-advies en koersdoel van EUR14,50. Omstreeks 9.20 uur noteert het aandeel 0,1% lager op EUR11,73, terwijl de ASX met 0,3% daalt. (patrick.buis@wsj.com)


    Dow Jones Nieuwsdienst: +31-20-5715200; amsterdam@dowjones.com

  5. [verwijderd] 1 december 2015 22:35
    Shire (SHPG) Presents at Piper Jaffray 27th Annual Healthcare Brokers Conference
    www.seekingalpha.com/article/3724416

    Jeff Poulton - Shire Chief Financial Officer
    So again, I think the last 2 or 3 years in terms of the types of deals that we’ve done are pretty good reflection of what you should expect from us going forward.
    David Amsellem
    Okay that’s helpful. So, you recently announced the acquisition of Dyax and so that’s something else that’s top of mind. And I think you’ve addressed this, but I think it’s important to bring this up again. So, I guess there is a question here is how concern should we be that the sustainability of CINRYZE? And is the Dyax transaction maybe something of passed at admission [ph] that perhaps the ROI on the ViroPharma transaction may not be up to snuff. And that’s something that comes up a lot in my discussions with investors. How would you address that?

    Jeff Poulton - Shire Chief Financial Officer
    Let me start with DX-2930, the HAE Phase 3 ready asset that we got in acquisition with -- announced acquisition of Dyax. I think we’ve talked pretty clearly on the announcement call about the potential that we see there. We see it as a best in class therapy, assuming that the Phase 3 clinical results are consistent with what we saw in our earlier stage development. We see it potentially as a $2 billion peak revenue opportunity and we see the revenue coming from multiple sources, if you look at the market today. We think about a third of that will come from the prophylactic space which includes CINRYZE. And so, we do see this as a product that will cannibalize some of the CINRYZE business. And frankly that’s okay. I mean I think if you look at the financials associated with DX-2930 versus CINRYZE, you’ll see likely a product that will have much higher gross margins, given the manufacturing costs comparison between the two products. And you’ll also see a product in DX-2930 that’s got longer IP and regulatory protection. So, shifting business from CINRYZE to DX-2930 would be a good thing financially.
    We also think about a third of the business will come from patients that today are treated on the on demand products which there’s three or four of in the market today including FIRAZYR. And again, I think cannibalization of FIRAZYR would not be a bad thing. FIRAZYR in terms of the annual cost of therapy for patients that are on FIRAZYR will be lower than what it would be for DX-2930; and again, same situation in terms of IP and regulatory exclusivity. We’ve got regulatory exclusivity on FIRAZYR until 2018 and patent protection until 2020. So, longer duration for patients that shift to DX-2930. And then we think the final third comes from just general market expansion, more patients being diagnosed. We continue to see that today. And I think we’ll see that over the next 5 to 10 years that there’s going to be more patients on therapy. And we think DX-2930 is a best in class therapy will compete very effectively for those new patients that are diagnosed and go on treatment.
    In terms of ViroPharma, I think it’s a fair question and I understand why it’s being asked. I think when you do an acquisition you have to look at sort of comprehensively what you’ve acquired. And certainly CINRYZE for HAE was sort of the lead product that we acquired in that acquisition. I think it’s yet to be determined exactly how things are going to play out for CINRYZE. It’s possible that the sales, the competition that we’re seeing in the HAE space is developing faster than what we assumed two years ago when we did the deals. That could be a negative for CINRYZE. But I also think we acquired a pipeline and we’ve got three or four programs that are in late stage of development that frankly we didn’t attribute a lot of value to. First is a product for eosinophilic esophagitis which is entering Phase 3, rare GI disease that we think is a very attractive commercial opportunity. Maribavir for CMV infection is entering Phase 3, again attractive opportunity there. And then two new uses for CINRYZE, one an AMR that’s ready to enter Phase 3 and then one for NMO that’s in earlier stages of development. And I think all those things would be pluses versus what we assumed when we did the deals. So, I think it’s going to take a bit of time to play out to see whether or not the investments that we made there is going to have a return associated with it that we expected.
  6. [verwijderd] 2 december 2015 14:08
    14:05:02 / 02-12-15 Zafgen Says Another Patient Dies in Beloranib Study

    Zafgen Inc. said Wednesday that another patient died during a continuing study of a rare genetic disorder, two months after U.S. regulators temporarily halted its clinical trial to investigate circumstances surrounding the previous death.
    Shares, which closed Tuesday at $15.93, were down 43% in premarket trading.
    The biopharmaceutical company said it learned Tuesday that a patient being treated with beloranib for Prader-Willi syndrome was diagnosed with bilateral pulmonary emboli—blood clots to the lung—and died.
    The patient was receiving the drug during the open-label extension portion of the phase 3 trial.
    In October, Zafgen disclosed that a patient had died during the belanorib study. The U.S. Food and Drug Administration placed beloranib on partial clinical hold because of the thromboembolic events—blood clots that move after forming and block other vessels—in other trials of beloranib and the unknown nature of that death.
    On Tuesday, Chief Executive Thomas Hughes said Zafgen is in talks with the FDA while determining next steps for the program.
    "Our thoughts are with the patient and their family at this time," he said. "Patient safety remains our top priority and we are investigating the circumstances around this event."
    The company reiterated its expectation for "top-line results" of the randomized portion of the clinical trial in the first quarter of 2016.
    Write to Anne Steele at Anne.Steele@wsj.com
    Subscribe to WSJ: online.wsj.com?mod=djnwires
    (END) Dow Jones Newswires
    December 02, 2015 08:05 ET (13:05 GMT)
    © 2015 Dow Jones & Company, Inc.

    ZAFGEN INC.
    US98885E1038
  7. dmem2 2 december 2015 14:58
    quote:

    't zal maar gebeuren schreef op 2 december 2015 14:08:

    14:05:02 / 02-12-15 Zafgen Says Another Patient Dies in Beloranib Study

    Zafgen Inc. said Wednesday that another patient died during a continuing study of a rare genetic disorder, two months after U.S. regulators temporarily halted its clinical trial to investigate circumstances surrounding the previous death.
    Shares, which closed Tuesday at $15.93, were down 43% in premarket trading.
    The biopharmaceutical company said it learned Tuesday that a patient being treated with beloranib for Prader-Willi syndrome was diagnosed with bilateral pulmonary emboli—blood clots to the lung—and died.
    The patient was receiving the drug during the open-label extension portion of the phase 3 trial.
    In October, Zafgen disclosed that a patient had died during the belanorib study. The U.S. Food and Drug Administration placed beloranib on partial clinical hold because of the thromboembolic events—blood clots that move after forming and block other vessels—in other trials of beloranib and the unknown nature of that death.
    On Tuesday, Chief Executive Thomas Hughes said Zafgen is in talks with the FDA while determining next steps for the program.
    "Our thoughts are with the patient and their family at this time," he said. "Patient safety remains our top priority and we are investigating the circumstances around this event."
    The company reiterated its expectation for "top-line results" of the randomized portion of the clinical trial in the first quarter of 2016.
    Write to Anne Steele at Anne.Steele@wsj.com
    Subscribe to WSJ: online.wsj.com?mod=djnwires
    (END) Dow Jones Newswires
    December 02, 2015 08:05 ET (13:05 GMT)
    © 2015 Dow Jones & Company, Inc.

    ZAFGEN INC.
    US98885E1038
    wat heeft dit met Pharming te maken?
  8. forum rang 10 voda 4 december 2015 22:53
    Galapagos haalt bijna EUR600.000 op met uitoefening warrants.


    AMSTERDAM (Dow Jones)--Galapagos nv (GLPG.AE) kondigde vrijdag een kapitaalverhoging van bijna EUR600.000 aan als gevolg van de uitoefening van warrants.

    Op 4 december heeft het Belgisch-Nederlandse biotechbedrijf 63.500 nieuwe aandelen uitgegeven, met als gevolg een totale kapitaalverhoging van EUR590.800,00, inclusief uitgiftepremie.

    Daarmee bedraagt het maatschappelijk kapitaal EUR211.388.857,22.


    Door Dow Jones Nieuwsdienst; +31 20 5715 200; marleen.groen@wsj.com

  9. [verwijderd] 7 december 2015 20:04
    CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition
    - Data from ongoing extension study evaluate efficacy and long-term safety of rIX-FP when dosed up to once every 14 days for routine prophylaxis

    - The median annualized spontaneous bleeding rate (AsBR) was zero for all treatment intervals

    - rIX-FP demonstrates CSL Behring's promise to develop innovative specialty biotherapies that help people with serious medical conditions live full lives





    ORLANDO, Fla., Dec. 7, 2015 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and long-term safety of its investigational long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). The data, from an ongoing extension study and two pivotal Phase III studies, assessed rIX-FP for routine prophylaxis in previously-treated adults with hemophilia B, at dosing intervals of up to 14 days. The findings were presented during an oral presentation at the American Society of Hematology's (ASH) 57th ASH Annual Meeting and Exposition in Orlando, along with a second abstract reporting efficacy and safety results of rIX-FP in patients undergoing surgical procedures.

    "The findings from the ongoing extension study are promising and confirm the data we saw in our pivotal studies, with prolonged dosing intervals of up to 14 days with rIX-FP for routine prophylaxis," said Elena Santagostino, M.D., Ph.D., Professor in the Medical School of Clinical and Experimental Hematology at the University of Milan/IRCCS Maggiore Hospital, and lead investigator. "rIX-FP has been developed with a pharmacokinetic profile that allows for less frequent dosing. Through this ongoing study, we are continuing to evaluate longer treatment intervals and the potential impact on preventing bleeding in select patients."

    Key Study Findings
    •Efficacy and safety of rIX-FP in previously-treated children, adolescents, and adults (Oral Presentation Abstract #548): The first abstract reported on two completed Phase III studies (CSL654-3001 and CSL654-3002) assessing the safety and efficacy of rIX-FP for prophylaxis treatment in previously-treated patients (ages 1 to 61) with hemophilia B (factor IX activity =2%). The first study (CSL654-3001) included 63 patients, ages 12 to 61. These patients either received prophylaxis treatment (once every seven days for six months and then, if eligible, a 10- or 14-day prophylaxis treatment interval for 12 to 18 months) or only on-demand treatment for six months and then switched to seven-day prophylaxis treatment. The second study (CSL654-3002) included 27 children (ages 1 to 11) who received seven-day prophylaxis treatment for approximately 12 months. Overall, the median annualized spontaneous bleeding rate (AsBR) was 0.00 for all treatment intervals.

    During the extension study, 76 patients from the phase III studies continued their prophylaxis regimen but additional patients switched to longer treatment intervals, including the 10- and 14-day intervals in patients younger than 12 and more prolonged treatment intervals in patients older than 18. At least 50 patients achieved 100 exposure days of treatment without developing an inhibitor to factor IX or antibodies to rIX-FP. Overall, no serious adverse reactions were seen during the studies and favorable long-term tolerability was demonstrated.

    "At CSL, we focus our world-class research and development to help people with serious medical conditions, such as hemophilia B, live full lives," said Dr. Andrew Cuthbertson, Chief Scientific Officer and Director of R&D, CSL Limited. "These latest results from our pivotal research program demonstrate the potential for rIX-FP to help patients maintain factor IX levels over a long period of time with greater freedom from frequent infusions. This is an important attribute for patients who require a prophylactic regimen but don't want treatment to disrupt their active lives."
    •rIX-FP in previously-treated patients undergoing surgery (poster presentation abstract #2298): The second abstract reported on a surgical sub-study included in the Phase III studies, including the ongoing extension study, as part of the global PROLONG-9FP clinical program. This abstract evaluated the use of rIX-FP in five major orthopedic surgeries to prevent bleeding during and post-surgery in four patients with hemophilia B. For all procedures, the investigators rated the response as "excellent" or "good," and a single pre-operative dose of rIX-FP maintained hemostasis during surgery. Over the 14-day perioperative period, patients needed six or seven infusions. The median rIX-FP consumption prior to surgery and post-surgery was 340 IU/kg, which was lower than with conventional therapies. None of the patients developed inhibitors to factor IX or antibodies to rIX-FP.

    About Hemophilia B
    Hemophilia B is a congenital bleeding disorder characterized by deficient or defective factor IX; nearly all affected patients are male. People with hemophilia B may experience prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. According to U.S. Centers for Disease Control and Prevention, the condition affects approximately one in 25,000 male births.

    About rIX-FP
    CSL Behring engineered rIX-FP to extend the half-life of recombinant factor IX through genetic fusion with recombinant albumin. CSL Behring selected albumin as its recombinant genetic fusion partner due to its long physiological half-life. In addition, albumin has been shown to have a favorable tolerability profile, low potential for immunogenic reactions and a well-known mechanism of clearance. The cleavable linker connecting recombinant factor IX and recombinant albumin has been specifically designed to preserve the native function of the coagulation factor in the fusion protein, while benefiting from recombinant albumin's long physiological half-life.

    The U.S. Food and Drug Administration, European Medicines Agency and Swissmedic are currently reviewing CSL Behring's license applications for rIX-FP. For more information about CSL Behring's recombinant coagulation factor products in development to treat hemophilia, visit www.cslbehring.com/products/bleeding-...

    About CSL
    CSL (ASX:CSL) is a leading global biotherapeutics company with a dynamic portfolio of life-saving innovations, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses CSL Behring and Seqirus — operates in over 30 countries with more than 14,000 employees. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

    For more information about CSL Behring visit www.CSLBehring.com or follow us at www.Twitter.com/CSLBehring.
  10. forum rang 10 voda 8 december 2015 16:15
    Galapagos boekt succes met medicijn tegen ziekte van Crohn

    AMSTERDAM (Dow Jones)--De tussentijdse analyse in de Fase 2 studie voor medicijn filgotinib van Galapagos nv (GLPG.AE) toont aan dat het middel werkzaam en veilig is als eenmaal daagse, orale behandeling bij matige tot ernstige ziekte van Crohn, zo meldt het biotechbedrijf.

    "Filgotinib is de eerste JAK-remmer die werkzaamheid laat zien in de ziekte van Crohn, een ziekte waarvoor vandaag de dag slechts enkele geneesmiddelen beschikbaar zijn," zegt Piet Wigerinck, CSO van Galapagos.

    Volgens Galapagos was sprake van een significante verbetering in klinische respons en kwaliteit van leven van patienten. Daarnaast is gebleken dat het veiligheidsprofiel van filgotinib vergelijkbaar is met eerdere studies.

    "Wij zijn er trots op dat we innovatieve geneesmiddelen kunnen brengen bij patienten bij wie nog een grote onvervulde medische behoefte bestaat. Wij zijn van plan om dit geneesmiddel zo snel mogelijk naar Fase 3 te brengen," zegt chief executive Onno van de Stolpe.

    Filgotinib is volledig eigendom van Galapagos. Het concern ontwikkelt het medicijn ook als behandeling voor reumatoide artritis. Voor die indicatie wordt de start voorbereid van een Fase 3 programma, gepland in de eerste helft van 2016.


    Door Ben Zwirs; Dow Jones Nieuwsdienst; +31-20-5715200; ben.zwirs@wsj.com

6.429 Posts
Pagina: «« 1 ... 135 136 137 138 139 ... 322 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Logische herfinanciering Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links